Only one [14] of our included articles reported the prognosis of R/R IDH-mutated AML patients treated with IDH inhibitors combined with other anticancer drugs, and 5 of 19 patients (26%) achieved complete remission. The gene discussed is IDH2; the disease is acute myeloid leukemia.